Product Description
This is an arylsulfonamide gamma -secretase inhibitor that was reported to selectively block processing of the enzyme's APP substrate, relatively sparing Notch processing. (Sourced from: https://www.alzforum.org/therapeutics/avagacestat)
Mechanisms of Action: G-Secretase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2009-010067-16 | P2 |
Completed |
Alzheimer Disease |
2013-07-09 |
|
| CN156-018 | P2 |
Terminated |
Alzheimer Disease |
2013-07-01 |
|
| CN156-029 | P1 |
Completed |
Alzheimer Disease |
2010-12-01 |
|
| 2008-005929-11 | P2 |
Completed |
Alzheimer Disease |
2010-06-07 |